GleamWall
中文EN

AZN ASTRAZENECA PLC IFRS

Pharmaceutical Preparations · NYSE · SEC CIK 901832 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY8.6%
TTM net income YoY45.3%
TTM EPS YoY45.3%
Revenue 3-yr CAGR9.8%
Net income 3-yr CAGR46.0%

Margins

Gross margin81.9%
Operating margin23.4%
Net margin17.4%
FCF margin20.0%
EBITDA margin—

Returns

ROE22.9%
ROA9.4%
ROIC (approx.)16.8%
Asset turnover0.54x

Leverage & solvency

Liabilities / assets57.3%
Debt / equity0.57x
Current ratio0.94x
Interest coverage8.11x

Cash quality & payout

Operating cash flow / net income1.43x
Accruals ratio-4.0%
Payout ratio48.6%
Capex / revenue4.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q22025-06-302024Q22024-06-302023Q22023-06-302022Q22022-06-302021Q22021-06-302021Q12021-03-312020Q42020-12-312020Q32020-09-30
Income statement
Revenue$14.46B$12.94B$11.42B$10.77B$8.22B$7.26B$7.01B$6.52B
Cost of revenue$2.47B$2.18B$1.96B$3.00B$2.19B———
Gross profit$11.98B$10.76B$9.46B$7.77B$6.03B———
R&D expense$3.55B$3.01B$2.67B$2.55B$1.83B———
SG&A expense$4.86B$4.93B$4.99B$4.68B$3.10B———
Operating income$3.51B$2.75B$2.46B$539.00M$1.13B———
Interest expense$439.00M$443.00M$431.00M$311.00M$326.00M———
Pretax income$3.13B$2.40B$2.09B$247.00M$764.00M———
Income tax$679.00M$469.00M$268.00M-$113.00M$214.00M———
Net income$2.45B$1.93B$1.82B$360.00M$550.00M———
EPS (basic)1.581.241.170.230.42———
EPS (diluted)1.571.241.170.230.42———
Weighted avg. shares (diluted)1.56B1.56B1.56B1.56B1.32B———
Balance sheet
Cash & equivalents$7.06B$6.92B$5.66B$4.82B$15.57B—$7.83B—
Short-term investments$50.00M$160.00M$148.00M$70.00M$62.00M—$160.00M—
Receivables$14.17B$11.05B$11.09B$8.91B$6.36B—$7.02B—
Inventory$6.47B$5.67B$5.05B$6.22B$4.76B—$4.02B—
Current assets$28.94B$25.39B$22.84B$20.92B$27.27B—$19.54B—
PP&E, netmay include right-of-use assets (IFRS)$11.64B$9.63B$8.68B$8.72B$8.36B—$8.25B—
Goodwill$21.22B$21.06B$19.96B$19.82B$11.80B—$11.85B—
Intangibles$37.92B$39.43B$38.33B$39.90B$20.01B—$20.95B—
Total assets$112.42B$104.34B$96.54B$96.58B$73.64B—$66.73B—
Current liabilities$33.54B$28.57B$26.38B$21.82B$22.22B—$20.31B—
Short-term debt$6.49B$5.07B$4.56B$2.16B$2.70B—$2.19B—
Long-term debt$24.71B$27.23B$24.33B$26.46B$24.11B—$17.50B—
Total debt$31.21B$32.29B$28.89B$28.62B$26.80B—$19.70B—
Total liabilities$67.61B$64.74B$59.13B$60.63B$57.95B—$51.09B—
Shareholders' equity$44.72B$39.51B$37.39B$35.93B$15.68B—$15.62B—
Net debt$24.15B$25.38B$23.22B$23.81B$11.24B—$11.87B—
Cash flow statement
Operating cash flow————————

Free plan shows the latest 8 periods; Pro shows all 26 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.